GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more
GeneMatrix Inc (109820) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.027x
Based on the latest financial reports, GeneMatrix Inc (109820) has a cash flow conversion efficiency ratio of 0.027x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩500.19 Million) by net assets (₩18.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneMatrix Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how GeneMatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GeneMatrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneMatrix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Earlyworks Co., Ltd. American Depositary Shares
NASDAQ:ELWS
|
-1.245x |
|
Habco Trans Maritima
JK:HATM
|
0.017x |
|
Wotso
AU:WOT
|
0.034x |
|
Anli International Co Ltd
TWO:5223
|
-0.017x |
|
577 Investment Corp
VN:NBB
|
-0.230x |
|
Copper Mountain Mining Corporation
PINK:CPPMF
|
-0.079x |
|
Ugint Co Ltd
KQ:195990
|
-0.008x |
|
Ulaslar Turizm Yatirimlari ve Dayanikli Tuketim Mallari Ticaret Pazarlama AS
IS:ULAS
|
0.018x |
Annual Cash Flow Conversion Efficiency for GeneMatrix Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of GeneMatrix Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩19.23 Billion | ₩-200.12 Million | -0.010x | +89.73% |
| 2023-12-31 | ₩23.15 Billion | ₩-2.35 Billion | -0.101x | -139.49% |
| 2022-12-31 | ₩24.19 Billion | ₩-1.02 Billion | -0.042x | -140.59% |
| 2021-12-31 | ₩32.32 Billion | ₩3.37 Billion | 0.104x | -22.75% |
| 2020-12-31 | ₩33.39 Billion | ₩4.51 Billion | 0.135x | +190.33% |
| 2019-12-31 | ₩15.25 Billion | ₩-2.28 Billion | -0.149x | +40.89% |
| 2018-12-31 | ₩10.83 Billion | ₩-2.74 Billion | -0.253x | -57.59% |
| 2017-12-31 | ₩11.06 Billion | ₩-1.77 Billion | -0.160x | -436.38% |
| 2016-12-31 | ₩12.48 Billion | ₩-373.25 Million | -0.030x | +49.30% |
| 2015-12-31 | ₩10.04 Billion | ₩-591.96 Million | -0.059x | +49.01% |
| 2014-12-31 | ₩11.89 Billion | ₩-1.38 Billion | -0.116x | -- |